close

Agreements

Date: 2018-10-25

Type of information: Nomination

Compound: member of the board of directors

Company: Disarm Therapeutics (USA - MA)

Therapeutic area: Neurological diseases - Neurodegenerative diseases

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On October 25, 2018, Disarm Therapeutics announced that Robert Copeland and Kimi Iguchi have joined its board of directors.
  • Dr. Copeland is a prolific drug hunter, having brought 18 drugs into human clinical development with three NDA approvals to date. Most recently, he founded and leads Accent Therapeutics, a company translating RNA-modifying protein biology into new therapies for cancer.
  • Ms. Iguchi is a proven company builder. A chemist by training, she is the chief financial officer and treasurer at Sage Therapeutics, Inc., where she steered the company through its 2014 IPO and contributed to advancing four therapies into clinical development so far.
 

Financial terms:

Latest news:

Is general: Yes